GlassScriptPhysician profile
Kevin Goodluck
NPI 1710071196
$604.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $53.95 · 2021: $400.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $251.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $56.22 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $55.18 | 2019 | |
| Pfizer INC. | $45.61 | 2021 | |
| Amarin Pharma, INC. | $41.53 | 2019-2020 | |
| Lilly USA, LLC | $38.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.77 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $32.64 | 2021 | |
| Merck Sharp & Dohme LLC | $16.23 | 2019 | |
| Astellas Pharma US INC | $15.23 | 2019 | |
| Angiodynamics, INC. | $14.44 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Goodluck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.